Galapagos loses Roche and misses profit target
This article was originally published in Scrip
Galapagos of Belgium saw its share price slump as it hit investors with a double whammy: not only had it lost one of its five big pharma strategic alliance partners, Roche, but it had also failed to deliver on its 2012 income target. The broad-focused drug discovery and development company saw its share price slump 8.8% to €18.60 by midday trading on Euronext on 8 March.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.